0001062993-23-016018.txt : 20230808 0001062993-23-016018.hdr.sgml : 20230808 20230808165322 ACCESSION NUMBER: 0001062993-23-016018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230807 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SOOD NITIN CENTRAL INDEX KEY: 0001877433 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 231152249 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-08-07 0001478320 Adaptive Biotechnologies Corp ADPT 0001877433 SOOD NITIN C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE EAST SEATTLE WA 98109 0 1 0 0 Chief Commercial Officer, MRD 1 Common Stock 2023-08-07 4 S 0 5652 6.78 D 225358 D Common Stock 2023-08-08 4 S 0 10550 6.54 D 214808 D This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. /s/ Nitin Sood by Stacy L Taylor, Attorney-in-Fact 2023-08-08